I think this is one of the best quarterly reports RBM has ever had, real signs of 
improvement and a developing trend tpowards increaseing revenue.  Begining 
to get enthusiastic again.

~~ Dimar

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it
recorded total revenues of $1,471,130 and a net loss of $3,648,602 or
($0.03) per share for the three month period ended September 30, 2008.
Subsequent to the end of the third quarter, the Company announced the
close of a $5.1 million brokered and non-brokered private placement.

Corporate Update

"As part of what we expect to be a continued trend, we have recorded our
highest quarterly total and product revenues to date, with a 58% increase
in product revenues over the same period last year," said S. Wayne Kay,
Chief Executive Officer. "We have begun to recognize revenues from 3M's
launch of our flu A+B test and we are also preparing to begin clinical
trials for the next clinical application, also to be sold and marketed by
3M. In addition, we are preparing for the launch of our cardiovascular
product line in the Unites States, early next year by our partner for
cardiovascular products, Roche Diagnostics."

Continued Mr. Kay, "As expected, we will experience negative gross margins
as we cover increased overhead associated with the move to our
significantly larger production facility. We are transitioning the Company
to one that can meet our future projected needs. With anticipated needs of
our existing partners coupled with the demands of our other customers and
the prospects for new customers and products on the horizon, we are
planning for significant growth of our revenues. We believe our third
quarter results are consistent with the strategy that will generate the
best long-term results for our shareholders and our recent financing was
an important building block toward meeting future milestones."

For a further discussion of the Company's financial results for the three
and nine month periods ended September 30, 2008, please refer to the
Company's unaudited interim consolidated financial statements and related
MD&A, which can be found at www.responsebio.com, SEDAR (Canada)
www.sedar.com or EDGAR (U.S.) www.sec.gov/edgar/searchedgar/webusers.htm.
Information at these sites is typically available within 24 hours of the
distribution of the news release.